Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Mon, June 8, 2026 at 12:18 AM GMT+7 3 min read KRYS Is KRYS a good stock to buy?
- Krystal Biotech (KRYS) is a gene therapy company focused on rare diseases built around its proprietary HSV-1 vector platform, positioning it as a potential multi-product leader rather than a single-asset biotech.
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now? Ricardo Pillai Mon, June 8, 2026 at 12:18 AM GMT+7 3 min read KRYS Is KRYS a good stock to buy? We came across a bullish thesis on Krystal Biotech, Inc. on Investment Management Academy’s Substack. In this article, we will summarize the bulls’ thesis on KRYS. Krystal Biotech, Inc. s share was trading at $310.30 as of May 28th. KRYS’s trailing and forward P/E were 41.55 and 45.45 respectively according to Yahoo Finance.
Krystal Biotech (KRYS) is a gene therapy company focused on rare diseases built around its proprietary HSV-1 vector platform, positioning it as a potential multi-product leader rather than a single-asset biotech. Its commercialized therapy VYJUVEK for DEB already generates high-margin, recurring revenue per patient in a highly underserved ultra-rare population, with significant room for expansion as global patient identification and international reimbursement broaden access.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich